A new perspective in the treatment of dyslipidemia: Can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

Treatments in Endocrinology

Volumn 4, Issue 5, 2005, Pages 311-317

  Steiner, George ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; PROCETOFEN;

EID: 31144477416     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200504050-00004     Document Type: Review

References (49)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53
2. Betteridge DJ. Treating dyslipidaemia in the patient with type 2 diabetes. Eur Heart J Suppl 2004; 6 Suppl. C: C28-33
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
4. NCEP Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
5. Eberly LE, Cohen JD, Prineas R, et al. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848-54
6. Vaccaro O, Eberly LE, Neaton JD, et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screens of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004; 164: 1438-43
7. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939-42
8. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 27: plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683-7
9. Papadakis JA, Milionis HJ, Press M, et al. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus: a special reference to statins. J Diabetes Complications 2001; 15: 211-26
10. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 Suppl. 1: S68-71
11. Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354-9
12. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8
13. Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am 2004; 33: 545-55
14. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506
15. Watts GF, Mandalia S, Brunt JN, et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993; 42: 1461-7
16. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21
17. Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005; 28: 101-7
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
19. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10
20. Tenenbaum A, Fisman EZ. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc Diabetol 2004; 3: 10
21. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20
22. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-9
23. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16
24. Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62: 1909-44
25. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511
26. ALLHAT-LLT Trial Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007
27. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58
28. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96
29. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-3
30. Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 2004; 27: 2253-9
31. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93
32. Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003; 278: 17982-5
33. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-8
34. Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999; 15: 395-9
35. Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16: 763-72
36. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993; 13: 702-11
37. Packard KA, Backes JM, Lenz TL, et al. Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy 2002; 22: 1527-32
38. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate. The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care 1998; 21: 641-8
39. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357 (9260): 905-10
40. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8
41. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-604
42. Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-7
43. Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [ISRCTN64783481]. Cardiovasc Diabetol 2004; 3: 9
44. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2
45. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002; 90: 50K-60K
46. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50-7
47. Wen X, Wang JS, Backman JT, et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29: 1359-61
48. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280-7
49. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905